Autolus Therapeutics, a biopharmaceutical company specializing in next-generation T cell therapies, will release its first quarter 2026 financial results and operational highlights on May 14, 2026, before U.S. markets open. The company will host a conference call and webcast at 8:30am EDT to discuss the results and provide a business update. Autolus is known for its marketed therapy AUCATZYL® and is developing treatments for cancer and autoimmune diseases. This report will give investors insight into the company’s recent performance and strategic direction.
Aya Gold & Silver Inc., a Canadian precious metals mining company operating in Morocco, will be added to the VanEck Gold Miners ETF (GDX) effective June 19, 2026. This inclusion marks a significant milestone reflecting the company's growth in product...
Nephros, Inc. emphasizes its ultrafiltration technology's ability to capture microplastics and nanoplastics in water, following the U.S. EPA's April 2026 decision to list microplastics as a priority contaminant under the Safe Drinking Water Act. The ...
After the US and Iran reached a deal expected to reopen the Strait of Hormuz, the world's largest tanker owner, Mitsui OSK Lines, cautions that shipping companies will wait for proof the agreement works before resuming normal traffic. The strait is c...
YieldMax ETFs have announced their weekly distributions for Group 1 ETFs, with distribution rates ranging from about 25% to over 65%. These ETFs focus on option income strategies across sectors like semiconductors, AI, crypto, and metals. Investors s...
QTREX Quantum Ltd announced that its Additively Manufactured Electronics (AME) technology achieved a 97% yield validation at a major U.S. interconnect manufacturer. This milestone confirms the technology's readiness for high-demand production environ...
